Trial
NCT07410377
UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases
Early Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
The Affiliated Hospital of Xuzhou Medical University
Collaborators
Shanghai Xiniao Biotech Co., Ltd.
Condition
Systemic Lupus Erythematosus
Intervention
UCAR-T cells
Why stopped
Internal decision.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-28